MIRM (Mirum Pharmaceuticals) Accumulated Depreciation: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIRM Mirum Pharmaceuticals Inc MIRM
49 GF Score
Price $98.22
GF Value $82.40
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Accumulated Depreciation?

Mirum Pharmaceuticals MIRM -2.38% 49 Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus rates MIRM with a GF Score™ of 49/100 and a GF Value™ of $82.40 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Mirum Pharmaceuticals Accumulated Depreciation Related Terms

Mirum Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Accumulated Depreciation Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mirum Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MIRM
49GF Score
Mirum Pharmaceuticals Inc MIRM
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.0 Mil mean?
Mirum Pharmaceuticals (MIRM) has a Accumulated Depreciation of $0.0 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Accumulated Depreciation too high?
Mirum Pharmaceuticals' current Accumulated Depreciation is $0.0 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 49/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Accumulated Depreciation compare to DNTH and COGT?
Mirum Pharmaceuticals' Accumulated Depreciation of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Accumulated Depreciation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (MIRM) is currently considered Modestly Overvalued. The stock's GF Value™ is $82.40, compared to a current price of $98.22 — trading 19.2% above its estimated fair value. The current Accumulated Depreciation is $0.0 Mil. Mirum Pharmaceuticals' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Mirum Pharmaceuticals (MIRM), the current Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of $98.22 is trading 19.2% above its estimated GF Value™ of $82.40. GuruFocus considers Mirum Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MIRM:

  • Accumulated Depreciation: $0.0 Mil
  • GF Value™: $82.40 vs. price of $98.22 (19.2% above fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges 08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
49GF Score

Get the complete analysis for MIRM

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$98.22
Price
$82.40
GF Value